STC Stem Cell Treatment & Research Institute

Name

STC Stem Cell Treatment & Research Institute

Legal name

bBHC INC.

Website

https://stcstri.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Health Services (8000)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Stem cell therapy
• Regenerative medicine
• Pluripotent stem cells
• Cell processing services
• Clinical stem cell research

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Stem Cell Treatment Services: Direct patient treatment services through KFDA-approved cell processing facility. Patients receive stem cell-based treatments for various conditions including cancer, diabetes, Parkinson's disease, liver disease, kidney disease, cartilage issues, and skin rejuvenation.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

STRI provides disease-specific stem cell treatment services built on its proprietary KHCs (Korean Human Cells) pluripotent stem cell platform, delivered through a KFDA-approved cell processing facility in Seoul. The institute treats indications including cancer, Parkinson's disease, liver disease, diabetes (Type I and II), kidney disease, cartilage damage, and skin cell rejuvenation, and also markets an ancillary Energy Water consumer product.

Product overview

STRI is a stem cell treatment and research institute offering a unified platform of stem cell-based therapies and products. The core technology is KHCs (Korean Human Cells), a pluripotent stem cell platform that is mass producible and side-effect-free, approved by KFDA for cell processing and human cell care. The portfolio includes disease-specific treatment services (Cancer, Down-Aging, Liver Disease, Parkinson's, Diabetes, Kidney Disease, Cartilage, Skin Cell Rejuvenation), an Energy Water product, and the proprietary nEPS technology for overcoming cancer. The institute positions itself as a life sciences company aiming for youthful 120 years and healthy 140 years of age.

Differentiator

Problem solved

Functional benefit

Products and services

• Stem Cell Cancer Treatment Stem cell-based treatment research and therapy for cancer, applying STRI's KHCs and nEPS pluripotent stem cell platforms to address the disease; offered to patients seeking advanced regenerative therapy options at the Seoul facility.
• Down-Aging Treatment Anti-aging regenerative treatment using stem cells, with STRI positioning KHCs as a stronger alternative to UCMSCs for down-aging applications; targeted at adult patients seeking age-related regeneration therapies.
• Liver Disease Treatment Stem cell therapy targeting liver cirrhosis, liver damage, fibrosis, and reduced liver function, delivered through STRI's cell processing capability for patients with chronic liver conditions.
• Parkinson's Disease Treatment Treatment for Parkinson's disease utilizing KHCs that can differentiate into neuronal cells; intended for patients seeking regenerative neurology options beyond conventional therapy.
• Diabetes Treatment Novel stem cell therapy for Type I and Type II diabetes addressing chronic high blood sugar conditions; positioned as a regenerative alternative for patients with limited response to conventional management.
• Kidney Disease Treatment Stem cell-based treatment for kidney disease targeting conditions where the kidneys cannot properly perform their functions; offered to patients with chronic kidney impairment seeking regenerative options.
• Cartilage Treatment Stem cell therapy for cartilage regeneration and repair, intended for patients with cartilage damage or degeneration seeking regenerative joint restoration.
• Skin Cell Rejuvenation Stem cell treatment for skin cell rejuvenation targeting youthful appearance and anti-aging; positioned within bBHC's broader life sciences longevity goal of youthful 120 years and healthy 140 years.
• Energy Water An energy water consumer wellness product sold by STRI as part of its portfolio, complementing its core stem cell treatment services.

Quantifiable outcome

• Efficacy and safety demonstrated in published research for skin conditions, stroke, Bell's palsy, syringomyelia, psoriasis, and alopecia

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Global Research CenterscoreStrategic or Co-development PartnerSTRI actively seeks collaborative research partnerships with global research centers to advance stem cell technology and develop novel treatments for incurable diseases. The company welcomes these partnerships to bring their vision of extending healthy human lifespan into reality.
• Multinational Pharmaceutical CompaniescoreStrategic or Co-development PartnerSTRI welcomes collaborative research opportunities with multinational pharmaceutical companies to develop and commercialize stem cell-based treatments. These partnerships aim to overcome incurable diseases and bring innovative therapies to market.

Scale indicators3 records

Recent moves1 record

Expansion highlights4 records

Market position

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCW6Hk_WoAa6RuNCKDid4glQ
• Facebookfacebook.com/bBHCSTRI
• LinkedInlinkedin.com/company/stri

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STC Stem Cell Treatment & Research Institute